20 semaglutide FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products Weight loss drug could reduce
Description
A: Clinical trials show weight loss ranging from 5% to over 20% of body weight, depending on the medication and individual factors
Rang H, Dale M, Flower R, Henderson G
March 8, 2025
In August, drug manufacturer Eli Lilly began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro, according to Reuters
Do not assume symptoms represent routine medication side effects
unopened pens left at room temperature should be assessed by a healthcare professional before use
